The Charles R. Drew University (CDU) and the UCLA Jonsson Comprehensive Cancer Center has forged a strong and sustainable partnership to Eliminate Cancer Health Disparities in minority and underserved populations. Our partnership began in 2003 with support from the National Cancer Institute to initiate U56 collaboration, followed by a U54 award in 2009 to establish a long lasting comprehensive partnership. In addition, institutional investment from UCLA-JCCC and CDU has made it possible for a sustainable partnership to accomplish significant goals related to reducing cancer health disparities. Hence, in our renewal application, we propose to continue the momentum and do more to address cancer health disparities in our communities in Los Angeles County, and in particular South Los Angeles. The overarching goals of the CDU-UCLA Cancer Partnership Program are to significantly increase the number of scientists in cancer research and to enhance the cancer research and infrastructure capacity at Charles Drew University of Medicine and Science that will continue to address significant disparities in cancer among minority populations. Supported and implemented by an Administrative Core, Planning and Evaluation Core, and Research Projects, Research Education Core, Outreach Core, and Shared Resources Core. The five priorities for the partnership are: Priority 1: Increase the number and quality of cancer research projects at CDU by supporting full and pilot projects and increase the number of cancer researchers at CDU. Priority 2: Enhance research capability of the CDU's Integrated Clinical and Biomarker/ Biorepository Tissue and Data Resources focused on cancer health disparities research, education and outreach among underrepresented populations. Priority 3: Create institutional capacity at CDU for performing cancer-related clinical trials by leveraging the community and existing clinical research facilities and resources. Priority 4: Expose undergraduate and medical students, fellows, and faculty to cancer research and encourage them to pursue or advance their careers in this area, and implement a formalized mentorship program whereby junior research investigators are counseled and mentored during their career development. Priority 5: Bring culturally and linguistically appropriate cancer research information to the community and increase community capacity to develop and implement culturally appropriate health prevention strategies through community-partnered participatory research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54CA143931-06
Application #
9037345
Study Section
Special Emphasis Panel (ZCA1-PCRB-C (O1))
Program Officer
Ojeifo, John O
Project Start
2009-09-29
Project End
2020-08-31
Budget Start
2015-09-25
Budget End
2016-08-31
Support Year
6
Fiscal Year
2015
Total Cost
$1,808,129
Indirect Cost
$548,109
Name
Charles R. Drew University of Medicine & Science
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
La, V; Fujikawa, R; Janzen, D M et al. (2017) Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis Oncol 1:
Wang, Piwen; Solorzano, Walter; Diaz, Tanya et al. (2017) Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp 13:1-11
Wu, Yanyuan; Tran, Trinh; Dwabe, Sami et al. (2017) A83-01 inhibits TGF-?-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat 163:449-460
Maxwell, Annette E; Young, Sandra; Moe, Emily et al. (2017) Understanding Factors that Influence Health Care Utilization Among Mixtec and Zapotec Women in a Farmworker Community in California. J Community Health :
Dong, Yunzhou; Wu, Yong; Cui, Mei-Zhen et al. (2017) Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21. Mediators Inflamm 2017:2754756
Brennen, W Nathaniel; Zhang, Baohui; Kulac, Ibrahim et al. (2017) Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget 8:46710-46727
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Wu, Yong; Yu, Xiaoting; Yi, Xianghua et al. (2017) Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res 77:1383-1394
McGhee, Eva; Harper, Hill; Ume, Adaku et al. (2017) Elimination of Cancer Health Disparities through the Acceleration of HPV Vaccines and Vaccinations: A Simplified Version of the President's Cancer Panel Report on HPV Vaccinations. J Vaccines Vaccin 8:

Showing the most recent 10 out of 79 publications